Connect with us

Utah

Gordon Monson: How will BYU, Utah and Utah State hang in as the world of college sports revolves around money? Will you, as a fan, hang in?

Published

on

Gordon Monson: How will BYU, Utah and Utah State hang in as the world of college sports revolves around money? Will you, as a fan, hang in?


Are you ready for this, Utah and BYU and Utah State fans? Get ready. Your rooting world is about to be nudged off its axis.

And it will be OK — for some of you. Not all, some.

College sports is on the verge of transforming into something that could be more than a little off-putting to many college fans. Question is: Are you one of them?

The evidence of revolutionary change was all around, as the NCAA moved toward a multibillion-dollar settlement this week — from possible private equity involvement in athletic departments to revenue-sharing with college athletes, those athletes essentially becoming university employees, to backpay for past athletes being handed out to big contracts being offered and signed and sometimes allegedly reneged on by the powers that be, the powers you’re accustomed to cheering for.

Advertisement

Bottom line is, college sports will one day be professional sports.

And now athletic departments are looking for money to counter added expenses they’ll face on account of wanting to stay competitive while being made legally to share proceeds with athletes, as well as other costs of competition.

Private equity partnership is being explored by some schools, where firms would pour millions of dollars into athletic departments as a means of investment, and be rewarded with payouts from money gained by those departments in the years ahead. This has been whispered about for a long time, but some administrators, needing more revenue to remain competitive for the aforementioned reasons, reportedly are seriously considering this idea. Such investment makes you wonder how much say those firms would have in overall direction of individual teams inside departments, in decision-making, etc.

Think of it like this: If the University of Utah partnered with a private equity outfit that offered to throw $150 million at Utah sports, and the Utes used that money to offset, say, sharing revenue and other expenses, say, paying coaches’ salaries, would that firm then have influence over who was hired for what position or who was fired?

Already mega-boosters are waist-deep in donating money at many schools. What kind of sway do they hold over department decisions? Would private equity investment make matters better or worse? In football, would it possibly balance out an annual competitive chase for league and national titles that currently rests at the same familiar 10 to 15 teams, inflating it to four times that many? Is more money magic?

Advertisement

It certainly wouldn’t hurt, unless it certainly would, what with powerful money men and women sinking their teeth into college sports. Would Utah then be Utah’s team, would it be your team, or would it be some investment group’s team?

Nobody’s completely sure.

But, either way, money is becoming even more important moving forward than it’s been in the past. In the redistribution of that money, now with athletes getting a significant share, maybe more athletes than ever before depending on scholarship limits or a lack of them, high-level departments that used to put cash wherever they wanted, might feel panicked by losing some 25 percent of it to the kids they so often say they care so deeply about.

Indeed, college football and basketball have always been about money. Now it’s about who gets what portion of that money. Does it bother fans — you — that a good measure of that money will be mandated to go to athletes? And what if a pile of that money went to private investors?

Does anybody really care as long as winning — or an increased prospect of it — is achieved?

Advertisement

We get it. It’s all an adjustment.

Some fans have always wanted their college athletes to play for their school for the same reasons the fans cheer for it with such emotion — because they identify with it, because they feel connected to it, because it represents them, because they love it, because they want it to win.

While winning at their sport is a big deal to most college athletes, winning at life is an even bigger deal. And winning at life is defined by many of them via how much money they can get. The example so often set by their coaches is Exhibit A. Top coaches make a ton of cash and top players want the same.

That money has to come somehow, from somewhere.

The glory of the school? Puh-leease.

Advertisement

An example:

Perhaps you saw the recent paraphrased headline in The Tribune that read about like this: “QB alleges false promises by coach, others in lawsuit.”

If you had read something like that regarding a complaint by a college quarterback aimed at his coach 15 or 20 years ago, you would have thought it was a deal where an overzealous coach promised a recruit a certain amount of playing time straight from the start. Maybe the coach told the high school kid he would not only get an opportunity to start as a freshman, but that he would, in fact, start. All he had to do was sign right here on the dotted line and the job was his. Next thing, he does not start and the coach’s promise is broken.

No. That was so 1995, so 2005, so 2010.

In 2024, the false-promises lawsuit is about cold, hard cash, according to a report by The Athletic’s Stewart Mandel, money that was allegedly pledged to quarterback Jaden Rashada by Florida coach Billy Napier and others, including a big Gators booster and the Gator Collective, all as a means of getting the recruit to sign with Florida instead of Miami, where he had earlier committed, which through a booster of its own had previously promised money to Rashada to sign with the Hurricanes.

Advertisement

How much money? The report said Florida, via its booster, offered the quarterback $13.85 million, outdoing Miami’s booster by some $4 million.

So, how’re you feeling about college sports these days?

This is not your dad’s college football. Back then, in the good ol’ days, programs would simply slip some bills into an envelope and quietly hand them over to a recruit to seal a deal. Now, we have … this.

But how much different in terms of competitive balance is it, really?

After Rashada chose Florida the deal fell apart and the lawsuit is now filed, seeking more than $10 million in damages, alleging six counts of fraud and negligence against Napier and a group of others. The quarterback was released from his letter of intent at Florida last year, subsequently heading to Arizona State and now he announced he’s transferring to Georgia.

Advertisement

The question, then, is worth repeating: How’re you feeling about college sports, especially power football and basketball? Is all the money cavalierly being tossed around messing over the experience of rooting for your favorite college team?

Would an installed salary cap help or hurt?

Is the required money — funneled into revenue-sharing — now essentially being mandated by the courts and/or the threat of future lawsuits — and likely to be agreed to by all power conferences in order to avoid deeper monetary liabilities — mixed along with big sums of cash that could be garnered from investment firms and/or other sources enough to turn you and your interest away from college sports?

Will you view it as nothing more than pro sports, all as your ticket prices rise? Or does it not matter that your athletes playing for your school not only are being shown the money, but they’re also getting it? Are you envious because when you went to college, you worked two part-time jobs, one pumping gas and another sweeping floors in an administration building, as you paid tuition and completed a full-time class schedule? Are you a champion of athlete amateurism while the school pockets all the profits?

Yeah, are you ready for this and — who knows — maybe more? Get ready. It’s coming. It’s here.

Advertisement

Thing is, it’ll be OK. It will. Pay no attention to the bag man behind the curtain. One way or another, certainly in college football and basketball, the sports you really care about, money has always ruled the day. Yesterday, today, tomorrow. It looks now a bit different, but if the money comes, if the winning comes, your care-factor is bound to come alongside. Nothing revolutionary about that. At top college levels, altruism and amateurism have long been diminished, if not dead.

In the years ahead, you can pull for the poor, thrifty, gutty, little college underdog … if it doesn’t die, too.



Source link

Utah

Utah Jazz NBA Draft Preview: 2024

Published

on

Utah Jazz NBA Draft Preview: 2024


The Utah Jazz have an exciting night tomorrow because they have the 10th, 29th, and 32nd pick in the 2024 NBA Draft. the Jazz have been in several rumors regarding the draft. Some rumors suggest the Jazz will trade up for higher than pick number 10. Some rumors suggest the Jazz will package picks 29 and 32 for a higher second pick in the first round. The honest observation at this point is that the Jazz might do just about anything for the draft. Tune in tomorrow night from home or from the Delta Center to find out what the Jazz do in round one! To watch the draft, tune in to ABC or ESPN.

Round One Draft: 6 PM MST, June 26th

Round Two Draft: 2 PM MST, June 27th

Below are projections on who the Jazz could select with their 3 picks. The projections are based on the Jazz’s rumored interest and generally where players are projected to be picked.

10th Pick Projections:

Advertisement

Photo by David Becker/NBAE via Getty Images

Advertisement

Ron Holland

Nikola Topic

Rob Dillingham

Cody Williams

Zach Edey

Advertisement

Dalton Knecht

2024 NBA Combine

Advertisement

Photo by Kamil Krzaczynski/NBAE via Getty Images

29th Pick Projections:

Advertisement
2024 NBA Combine

Photo by Jeff Haynes/NBAE via Getty Images

Advertisement

Kyshawn George

Ryan Dunn

Baylor Scheierman

AJ Johnson

Justin Edwards

Advertisement

Cam Christie

Tyler smith

Johnny Furphy

Advertisement
Notre Dame v Virginia

Photo by Ryan M. Kelly/Getty Images

Advertisement

Pick 32 Projections:

2024 NBA Combine

Advertisement

Photo by Jeff Haynes/NBAE via Getty Images

Picks 29 and 32 are close so these projections mainly overlap.

Harrison Ingram

Kyle Flipowski

Advertisement

Trentyn Flowers

Jonathan Mogbo

Jaylon Tyson

Tyler Kolek

Bronny James

Advertisement

Bobi Klintman

2024 NBA Combine

Advertisement

Photo by Kamil Krzaczynski/NBAE via Getty Images

Final Prediction

This projection could be way off because this draft has a lot of parity and the Jazz could very well trade some of their picks. With that said, I predict that the Jazz select Nikola Topic with the 10th pick. For the 29th pick, The Jazz go for Ryan Dunn. For the 32nd pick, I predict that the Jazz select Jaylon Tyson. I think the Jazz will almost make a trade or two tomorrow but don’t quite pull the trigger.

Advertisement

Houston Rockets v Utah Jazz

What do you think the Jazz will do tomorrow night? Comment below!



Source link

Advertisement
Continue Reading

Utah

4 Utah Jazz rumors to watch before the NBA Draft

Published

on

4 Utah Jazz rumors to watch before the NBA Draft


The Tribune’s Andy Larsen breaks down the latest reports.

(Francisco Kjolseth | The Salt Lake Tribune) Brooklyn Nets forward Mikal Bridges (1) tries to evade the block attempt by Utah Jazz center Walker Kessler (24) during NBA basketball in Salt Lake City Monday, Dec. 18, 2023.

The NBA Draft starts Wednesday, and the rumor mill is heating up around the Utah Jazz. Here’s the latest news, along with my reaction to the possibilities.

Trading for Mikal Bridges?

Rumor: Yahoo’s Jake Fischer reported that the Jazz are one of the teams interested in trading for Brooklyn wing Mikal Bridges, along with Houston and New York. Bridges is one of “Utah’s most aggressive aspirations,” Fischer wrote.

Advertisement

Reaction: The Nets have repeatedly declined to trade Bridges despite it probably making sense for the franchise to do so. Instead, they’ve been asking for more than three first-round picks in return for the 27-year-old.

Bridges would make the Jazz significantly better; he’s developed himself into a 20-point-per-game scorer while also being a solid defender. He’s the two-way player with size that these most recent playoffs have shown are extremely valuable. (Though we should note here that he was a far better player before the All-Star break than after it last year.)

The problem is that it’s not immediately clear that the Jazz would be a playoff team even with Bridges — he was an eight-win player last season, and the Jazz finished 15 wins short of the No. 10 seed. For an acquisition of Bridges to make sense, Utah would probably need to acquire other good players around him and Lauri Markkanen to get up in that 45-win range required to make the playoffs in the West. Still, it could be an exciting first step.

Trading for Zach LaVine?

Rumor: The Bulls “remain active” on trade negotiations sending out Zach LaVine involving the Jazz and the Philadelphia 76ers, according to NBC Sports Chicago’s K.C. Johnson. However, reporter Marc Stein disagreed with the report, saying he had been “advised to dismiss Utah’s interest.”

Reaction: Johnson’s a quality veteran reporter, but I agree with Stein. While I haven’t heard recent updates, Jazz personnel earlier this year indicated that LaVine wasn’t a logical option in the pre-trade deadline market given the Jazz’s place in the standings, LaVine’s poor record of availability, and especially his high contract that pays him a combined $138 million over the next three years.

Advertisement

Chicago Bulls’ Zach LaVine (8) scores past Toronto Raptors’ Gary Trent Jr. (33) during the first half of an NBA basketball In-Season Tournament game Friday, Nov. 24, 2023, in Toronto. (Frank Gunn/The Canadian Press via AP)

I don’t suspect circumstances have changed enough since to make a LaVine trade make sense now, at least not a trade in which the Jazz are giving up assets. If anything, it might require Chicago to send out assets to push the Jazz to take on LaVine’s deal.

Signing Tobias Harris?

Rumor: The Athletic’s Shams Charania reported that the Jazz and the Detroit Pistons “are expected to be the strongest suitors for Tobias Harris,” who is a free agent this summer after his 5-year, $180 million albatross of a deal ended with the 76ers.

Reaction: The Jazz will likely have about $40 million in cap space this summer. Some of that room the franchise anticipates using on Markkanen’s renegotiation and extension as the Finnish star enters the final year of his current contract.

Boston Celtics’ Al Horford (42) defends against Philadelphia 76ers’ Tobias Harris (12) during the first half of an NBA basketball game Friday, Dec. 1, 2023, in Boston. (AP Photo/Michael Dwyer)

Advertisement

Harris is theoretically someone who could help the Jazz. At this point in his career, he’s statistically pretty average across the board — his shooting, rebounding, passing, steals, and block rates are just around the 50th percentile, maybe a bit higher. Even average, though, would make Harris the Jazz’s best wing by a lot.

He turns 32 this summer, so Harris doesn’t make sense for the Jazz’s long-term future, and signing him would also mean fewer minutes for last year’s No. 9 pick, Taylor Hendricks. But if they could get him on a short-term deal for a discount, he could also be a tradable piece in a move later while helping the Jazz improve now.

Looking to move up?

Rumor: Multiple reporters indicated that the Jazz are looking to move up in the draft using the No. 29 pick and the No. 32 pick. First, ESPN’s Jonathan Givony reported Monday morning that the Jazz are looking to trade the two picks for a “pick in the late teens.” Arizona sports radio host John Gambadoro reported that he believed that the Suns had had discussions with the Jazz, sending the No. 22 pick to Utah for No. 29 and No. 32. Fischer, meanwhile, floated the idea of the Jazz acquiring No. 17 from the Lakers in exchange for the two picks.

Reaction: Jazz general manager Justin Zanik acknowledged that the club has reservations about having six first- or second-year players on the roster next season, the logical outcome if the team makes all three selections on Wednesday. So the Jazz consolidating these picks in this fashion follows that line of thinking, especially if they are targeting a player they believe is significantly better than what’s available around the turn of the draft.

My only concern is that, in general, teams trading up in drafts get a little less value than those trading down when you study the issue analytically. The NBA Draft Pick Trade Simulator at nbasense.com is a good tool for looking at this — trading No. 29 and No. 32 for No. 17 is a pretty fair deal, but trading those picks for No. 22 would be analytically a bad idea. That’s especially true in a “flat” draft, where players’ values are considered pretty close throughout the first round.

Advertisement

If the Jazz are going to defy the analytics, they should be really sure that the player they’re acquiring with the higher pick is worth giving up two chances to place bets further down in the draft.

Editor’s note • This story is available to Salt Lake Tribune subscribers only. Thank you for supporting local journalism.



Source link

Continue Reading

Utah

Comparing TriSalus Life Sciences (NASDAQ:TLSI) and Utah Medical Products (NASDAQ:UTMD)

Published

on

Comparing TriSalus Life Sciences (NASDAQ:TLSI) and Utah Medical Products (NASDAQ:UTMD)



TriSalus Life Sciences (NASDAQ:TLSI – Get Free Report) and Utah Medical Products (NASDAQ:UTMD – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings and valuation.

Profitability

This table compares TriSalus Life Sciences and Utah Medical Products’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
TriSalus Life Sciences N/A N/A -221.65%
Utah Medical Products 33.40% 13.06% 12.30%

Risk & Volatility

TriSalus Life Sciences has a beta of 0.55, meaning that its stock price is 45% less volatile than the S&P 500. Comparatively, Utah Medical Products has a beta of 0.14, meaning that its stock price is 86% less volatile than the S&P 500.

Advertisement

Analyst Recommendations

This is a summary of recent ratings and recommmendations for TriSalus Life Sciences and Utah Medical Products, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TriSalus Life Sciences 0 0 3 0 3.00
Utah Medical Products 0 0 0 0 N/A

TriSalus Life Sciences presently has a consensus target price of $13.33, indicating a potential upside of 129.10%. Given TriSalus Life Sciences’ higher probable upside, research analysts plainly believe TriSalus Life Sciences is more favorable than Utah Medical Products.

Earnings & Valuation

This table compares TriSalus Life Sciences and Utah Medical Products’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
TriSalus Life Sciences $21.98 million 7.19 -$59.04 million N/A N/A
Utah Medical Products $50.22 million 4.68 $16.64 million $4.50 14.79

Utah Medical Products has higher revenue and earnings than TriSalus Life Sciences.

Advertisement

Institutional and Insider Ownership

2.6% of TriSalus Life Sciences shares are held by institutional investors. Comparatively, 69.6% of Utah Medical Products shares are held by institutional investors. 76.2% of TriSalus Life Sciences shares are held by insiders. Comparatively, 6.6% of Utah Medical Products shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Utah Medical Products beats TriSalus Life Sciences on 6 of the 11 factors compared between the two stocks.

About TriSalus Life Sciences

(Get Free Report)

TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.

About Utah Medical Products

(Get Free Report)

Advertisement

Utah Medical Products, Inc. develops, manufactures, and distributes medical devices for the healthcare industry worldwide. It offers fetal monitoring accessories, vacuum-assisted delivery systems, and other labor and delivery tools; DISPOSA-HOOD infant respiratory hoods; and DELTRAN PLUS blood pressure monitoring systems. It also provides GESCO, an umbilical vessel catheters, including DIALY-NATE disposable peritoneal dialysis sets; PALA-NATE silicone oral protection devices; URI-CATH urinary drainage systems; NUTRI-CATHNUTRI-LOK feeding device; PICC-NATE, a percutaneous intraepithelial central venous catheter; MYELO-NATE lumbar sampling kits; HEMO-NATE disposable filters; and catheterization procedure tray of instruments and supplies. In addition, the company offers LETZ system to excise cervical intraepithelial neoplasia and other lower genital tract lesions; loop, ball, and needle electrodes; FILTRESSE evacuators; other specialty electrodes and supplies, and gynecologic tools; Femcare trocars, cannulae, laparoscopic instruments, and accessories; and EPITOME and OptiMicro electrosurgical devices. Further, it provides Filshie Clip female surgical contraception devices; PATHFINDER PLUS, an endoscopic irrigation devices; suprapubic catheterization; LIBERTY, an urinary incontinence treatment and control systems; ENDOCURETTE, a curette for uterine endometrial tissue sampling; TVUS/HSG-Cath to assess abnormal or dysfunctional uterine bleeding and other abnormalities of uterus; and LUMIN, a tool to manipulate the uterus in laparoscopic procedures. Additionally, it offers DELTRAN, a disposable pressure transducer; high-pressure and piezo-resistive transducer assemblies; and pressure monitoring accessories, components, and other molded parts. It serves neonatal intensive care units, labor and delivery departments, women’s health centers in hospitals, outpatient clinics, and physician’s offices. The company was incorporated in 1978 and is headquartered in Midvale, Utah.



Receive News & Ratings for TriSalus Life Sciences Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for TriSalus Life Sciences and related companies with MarketBeat.com’s FREE daily email newsletter.

Advertisement



Source link

Continue Reading

Trending